Company intelligence / Profile preview

NeuroEnergy Ventures

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

NeuroEnergy Ventures is launching its first commercial medical food, Neuridan, in late 2024 for the dietary management of impaired brain glucose metabolism in Alzheimer's Disease and mild cognitive impairment. The company has extensive clinical research supporting safety and additional preclinical/early clinical programs for other indications in neurology.

Therapeutic areas: Neurology
Modalities: Medical foodSmall moleculeKetone body ester
Industry: Biotech

Drug pipeline

1 asset

Neuridan

Unknown

Beyond the preview

Go deeper on NeuroEnergy Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroEnergy Ventures.

Explore the full profile